Gadoxetate Disodium

CHEMBL2103740 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
725.7 g/mol
LogP
Phase
4

This liver-specific gadolinium-based MRI contrast agent is taken up by functioning liver hepatocytes and excreted into bile, providing both vascular and hepatocyte-specific imaging phases. It is particularly useful for detecting and characterizing liver lesions, including small metastases and hepatocellular carcinoma.

น้ำหนักโมเลกุล

725.7000 g/mol

TPSA

220.00 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOC1=CC=C(C=C1)CC(CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Gd+3]

InChI

InChI=1S/C23H33N3O11.Gd.2Na/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;;;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);;;/q;+3;2*+1/p-5

Molecular Formula

C23H28GdN3Na2O11

HBD / HBA

- / 14

พันธะที่หมุนได้

4

อะตอมหนัก

40

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This liver-specific gadolinium-based MRI contrast agent is taken up by functioning liver hepatocytes and excreted into bile, providing both vascular and hepatocyte-specific imaging phases. It is particularly useful for detecting and characterizing liver lesions, including small metastases and hepatocellular carcinoma.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Gadoxetate Disodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2103740. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 91754427. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.